Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Metropolis Healthcare
Mid Cap•4,313 Employees•IPO 2019
Current Price
₹1808.60
-15.3 (-0.84%)Updated
Today's Range
1801
₹1808.60
1835
52 Week Range
52W Low₹1315.00
52W High₹2263.00
₹1808.60
Downside37.54%
Upside25.12%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹10,003.82 Cr
Market Cap
Total market value of companyP/E Ratio
59.46
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
7.36
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹32.40
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
5.92%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
14.70%
ROCE
Return on Capital Employed. >15% is goodNet Margin
10.74%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
2.19%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
9.22%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
23.20%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
18.70%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.15
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹256.94
Book Value
Net asset value per shareDividend Yield
0.25%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
48.90%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Metropolis Healthcare exhibits robust quarterly sales growth, with a 23.2% increase in the latest quarter, indicating strong demand for its services and a healthy market position within the healthcare sector.
- •The company boasts a healthy operating profit margin (OPM) of 22.4% and a Return on Equity (ROE) of 11.5%, demonstrating efficient cost management and strong pricing power in its operations.
Weaknesses
4 points- •The company's high Price-to-Earnings (P/E) ratio of 66.20 suggests the stock might be overvalued compared to its earnings, potentially making it vulnerable to market corrections and investor sentiment shifts.
- •Promoter holding at 48.9% is just below the ideal 50% threshold for complete control, which could potentially raise concerns about future corporate governance and strategic decision-making.
Opportunities
3 points- •The broader healthcare service provider industry offers significant growth potential, driven by increasing health awareness, an aging population, and expanding diagnostic demand across the region.
- •Compared to larger peers like Dr Lal Pathlabs (market cap 25919 Cr), Metropolis (market cap 10062 Cr) has substantial room to expand its market share and scale operations.
Threats
3 points- •The diagnostic sector is highly competitive, with peers like Dr Lal Pathlabs exhibiting higher ROCE (28.88%) and lower P/E (50.52), potentially pressuring Metropolis's margins and market position.
- •Foreign Institutional Investors (FIIs) have reduced their holding from 23.20% (2022) to 12.52% (2025), which could signal reduced foreign investor confidence or profit-booking, impacting stock sentiment.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
Duru Shah Family Trust | 26 Mar 2025 | 28 Mar 2025 | 57.30 L | 7.66 L | - | BUY |
Dr. Duru Sushil Shah | 26 Mar 2025 | 28 Mar 2025 | - | 7.66 L | - | SELL |
Sushil Shah Family Trust | 29 May 2025 | 02 Jun 2025 | 37.25 L | 11.67 L | - | BUY |
Sushil Kanubhai Shah | 29 May 2025 | 02 Jun 2025 | - | 11.67 L | - | SELL |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1896.73 | +₹88.13 | +4.87% |
| R3 | ₹1862.73 | +₹54.13 | +2.99% |
| R2 | ₹1848.87 | +₹40.27 | +2.23% |
| R1 | ₹1828.73 | +₹20.13 | +1.11% |
| PIVOT | ₹1814.87 | 6.27 | 0.35% |
| CURRENT | ₹1808.60 | - | - |
| S1 | ₹1726.73 | -₹81.87 | -4.53% |
| S2 | ₹1760.73 | -₹47.87 | -2.65% |
| S3 | ₹1780.87 | -₹27.73 | -1.53% |
| S4 | ₹1794.73 | -₹13.87 | -0.77% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+328.6% vs avg
1.54L
(13 Mar 2026)Delivery %+37.4% vs avg
93.4%
(13 Mar 2026)Avg Volume (20D)20-day average
0.36L
(13 Feb - 13 Mar)Avg Delivery %Trend ↑
56.0%
(13 Feb - 13 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Dr Lal Pathlabs Ltd
24,046.66 ₹ Cr
Best Profit Growth
Thyrocare Technologies Ltd
79.90 %
Highest Dividend Yield
Thyrocare Technologies Ltd
1.66 %
Peer Comparison
| Company Name |
|---|
 Krsnaa Diagnostics Ltd |
 Dr Lal Pathlabs Ltd |
 Suraksha Diagnostic Ltd |
 Thyrocare Technologies Ltd |
 Vijaya Diagnostic Centre Ltd |
About
Metropolis Healthcare Ltd
Metropolis Healthcare Limited is a leading provider of diagnostic services in India and internationally. Their core business revolves around offering a comprehensive range of clinical laboratory testing and profiling services to individuals and corporate clients. This includes a wide array of tests designed for various medical specialties and purposes.
The company's services cater to a broad spectrum of medical needs. They provide diagnostic services specializing in oncology (cancer), neurology (nervous system), gynecology (women's health), and nephrology (kidney disease). This specialized focus allows them to offer highly targeted and accurate testing for a variety of health conditions.
Beyond specialized testing, Metropolis also offers a comprehensive suite of health check-up packages. These packages are tailored to different demographic groups, including men, women, senior citizens, youth, and corporate employees. This approach allows for preventative health measures and early detection of potential health problems.
The diagnostic services provided by Metropolis play a crucial role in various stages of healthcare. Their tests are used for disease prediction, early detection through screening, confirming diagnoses, and monitoring the progression of existing conditions. This comprehensive approach contributes significantly to effective healthcare management.
In addition to their core diagnostic services, Metropolis also offers corporate wellness programs. These programs are designed to improve the health and well-being of employees within organizations. They also provide laboratory information system services and support clinical research initiatives, further expanding their reach within the healthcare ecosystem.
COMPANY FACTS - METROPOLIS
Registered Address
4th Floor, East Wing, Nirlon House,, Dr. Annie Besant Road, Worli,
Mumbai
MAHARASHTRA
IN
Tel: 918422801801
Website:https://www.metropolisindia.com/
Investor Relations:https://www.metropolisindia.com/investors
Company Details
Group: Health Care Equipment & Services
Sector: Health Care
Industry: Health Care Providers & Services
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 4,313
IPO Date: 15/04/2019
MANAGEMENT - METROPOLIS
Ms. Ameera Shah
Executive Chairman of the Board
Mr. Surendran Chemmenkottil
Chief Executive Officer
Mr. Sameer Patel
Chief Financial Officer
Dr. Nilesh Shah
President Internal Assurance and Advisor to Chief Executive Officer
Ms. Diya Suri
Chief People Officer
Mr. Pinakin Shah
Chief Information Officer
Mr. Mohan Menon
Chief Marketing Officer
Dr. Kirti Chadha
Chief Scientific Officer, Innovation Officer and Group Head CSR
Mr. Kamlesh Kulkarni
Compliance Officer, Company Secretary, Head - Legal and Secretarial
Mr. Kannan Alangadan
Chief Business Officer - South India
Mr. Avadhut Joshi
Chief Business Development Officer
Mr. Umesh Rai
Head - Emerging Business
Investor Questions Answered
Metropolis Healthcare Ltd (METROPOLIS) Stock FAQs
Get answers to the most common questions about Metropolis Healthcare Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Metropolis Healthcare Ltd (METROPOLIS) is ₹1,808.6. Today, the stock has declined by ₹15.30 (0.84%), trading in a range of ₹1,801 to ₹1,835. The stock opened at ₹1,825 with a trading volume of 1,53,578 shares.
Metropolis Healthcare Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹10,003.82 crores, P/E ratio of 59.46, ROE of 5.92%, and ROCE of 14.70%. The dividend yield stands at 0.25%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Metropolis Healthcare Ltd (METROPOLIS) is ₹2,263, while the 52-week low is ₹1,315. Currently trading at ₹1,808.6, the stock is 52.1% away from its 52-week low and 20.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Metropolis Healthcare Ltd stock at ₹1,808.6 depends on multiple factors. The stock is currently trading with a P/E ratio of 59.46 and P/B ratio of N/A. Today's performance shows a loss of 0.84%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Metropolis Healthcare Ltd offers a dividend yield of 0.25%, which means for every ₹100 invested at the current price of ₹1,808.6, you can expect to receive approximately ₹0.25 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Metropolis Healthcare Ltd's key financial metrics include: P/E Ratio: 59.46, P/B Ratio: N/A, ROE: 5.92%, ROCE: 14.70%, Dividend Yield: 0.25%, EPS: ₹32.40, Book Value: ₹256.94, Debt-to-Equity: 0.15, and Current Ratio: N/A. The company's market cap stands at ₹10,003.82 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Metropolis Healthcare Ltd stock opened at ₹1,825 and is currently trading at ₹1,808.6, showing a decline of ₹15.30 (0.84%). The intraday high is ₹1,835 and low is ₹1,801. The trading volume stands at 1,53,578 shares, indicating moderate market participation today.
Metropolis Healthcare Ltd has a Price-to-Earnings (P/E) ratio of 59.46, which means investors are willing to pay ₹59.46 for every ₹1 of earnings. With an EPS of ₹32.40, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Metropolis Healthcare Ltd has a market capitalization of ₹10,003.82 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹1,808.6) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Metropolis Healthcare Ltd has a book value of ₹256.94 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,808.6, which is 603.9% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Metropolis Healthcare Ltd has a Return on Equity (ROE) of 5.92% and Return on Capital Employed (ROCE) of 14.70%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Metropolis Healthcare Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Metropolis Healthcare Ltd has a debt-to-equity ratio of 0.15, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Metropolis Healthcare Ltd has an Earnings Per Share (EPS) of ₹32.40, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,808.6 and P/E ratio of 59.46, investors are paying 59.46 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Metropolis Healthcare Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Metropolis Healthcare Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Metropolis Healthcare Ltd stock, consider: 1) Fundamental Analysis - Review P/E (59.46), ROE (5.92%), debt-to-equity (0.15), and growth rates. 2) Technical Analysis - Check 52-week range (₹1315.00 - ₹2263.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1808.60) with book value (₹256.94) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Metropolis Healthcare Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,808.6 is 90330x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Metropolis Healthcare Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1315.00 - ₹2263.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.15 indicates leverage. 4) Liquidity Risk - Based on trading volume of 1,53,578 shares. 5) Valuation Risk - P/E of 59.46 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Metropolis Healthcare Ltd operates in the industry with key metrics: P/E ratio of 59.46, ROE of 5.92%, market cap of ₹10,003.82 crores, and dividend yield of 0.25%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.15), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Metropolis Healthcare Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,808.6, with a 52-week range of ₹1315.00 to ₹2263.00. Based on fundamentals like P/E (59.46), ROE (5.92%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Metropolis Healthcare Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1808.60. 2) Fundamental Deterioration - Declining ROE (currently 5.92%), increasing debt (D/E: 0.15), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Metropolis Healthcare Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.25%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu